Hixon Zuercher LLC Has $2.05 Million Holdings in Pfizer Inc. (NYSE:PFE)

Hixon Zuercher LLC lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 22.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 80,783 shares of the biopharmaceutical company's stock after buying an additional 14,753 shares during the period. Hixon Zuercher LLC's holdings in Pfizer were worth $2,047,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Bessemer Group Inc. increased its stake in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after purchasing an additional 13,228 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer during the 1st quarter valued at $8,283,000. Sage Mountain Advisors LLC lifted its holdings in shares of Pfizer by 7.3% in the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after purchasing an additional 1,404 shares in the last quarter. Penobscot Investment Management Company Inc. grew its holdings in shares of Pfizer by 2.7% during the first quarter. Penobscot Investment Management Company Inc. now owns 95,301 shares of the biopharmaceutical company's stock valued at $2,415,000 after buying an additional 2,527 shares in the last quarter. Finally, Brighton Jones LLC boosted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

PFE traded up $0.28 during trading on Wednesday, hitting $25.32. The stock had a trading volume of 36,581,486 shares, compared to its average volume of 41,577,377. The firm has a market cap of $143.95 billion, a PE ratio of 18.35, a P/E/G ratio of 0.91 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a 50 day simple moving average of $23.56 and a 200-day simple moving average of $24.83.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.82 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.79%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.